kwic
treatment
treatment
right
on
off
171
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for treatment out of >500 occurrences
677804 occurrences (No.8 in the rank) during 5 years in the PubMed. [cache]
[frequency of next (right) word to treatment]
677804 occurrences (No.8 in the rank) during 5 years in the PubMed. [cache]
| 171) Treatment with 1% TFA with/without 2% trii |
| 172) Treatment with AAA-derived metabolites in |
| 173) Treatment with Bacillus Calmette Guerin (B |
| 174) Treatment with DBZ suppressed CSE-dependen |
| 175) Treatment with anti-inflammatory corticost |
| 176) Treatment with leptin, acute or chronic, w |
| 177) Treatment with organic solvents and post t |
| 178) ed with cell death were identified by pre-treatment with the CDK4/6 inhibitor palboc |
| 179) in in wild-type mice without and with pre-treatment with the broad-spectrum MRP inhi |
| 180) Combined treatment with DAC and a Bcl2 inhibitor, v |
| 181) We show that long-term treatment with PARPi induces an inflammato |
| 182) of metabolites in SF mice associated with treatment with either LR or LGG. |
| 183) lly compares an intervention to a control treatment with equal numbers of patients r |
| 184) ation cycles, and each cycle comprised of treatment with high salt (Δ0.035 M NaCl) |
| 185) However, a two-week treatment with iloperidone (1 mg/kg ip.) p |
| 186) Two-week treatment with lithium chloride partially |
| 187) approaches combined with pharmacological treatment with synthetic adropin peptide. |
| 188) s been recent progress to find a curative treatment with the following approaches: 1 |
| 189) Short-term treatment with the necroptosis inhibitor, |
| 190) settings, and in breast cancer patients, treatment with the new anti-HER-2 drug tra |
| 191) with veliparib, a PARPi, to determine if treatment with this drug induces increased |
| 192) ldren and similarities and differences in treatment, with a focus on literature supp |
| 193) Treatment options for cocaine dependence a |
| 194) Several treatment options (n = 5) that do not in |
| 195) ood or saliva: their detection can affect treatment options and potential risk-reduc |
| 196) sin-aldosterone system (RAAS), multimodal treatment options are available with miner |
| 197) tudies and their relationships: different treatment options are illustrated as nodes |
| 198) Current treatment options are limited by the devel |
| 199) Current treatment options are limited in the face |
| 200) KI diagnosis in COVID-19 patients and new treatment options are required to reduce t |
| 201) patients with breast cancer, but optimal treatment options as well as risks associa |
| 202) k of non-pharmacological and non-invasive treatment options call for new and innovat |
| 203) The efficacy of several different treatment options can be assessed with eit |
[
right
kwic]
(1)68  of |
(13)7 planning |
(25)3 outcome |
(37)2 efficacy |
| (2)50 *null* | (14)6 to |
(26)3 protocols |
(38)2 goals |
| (3)29 and |
(15)4 approaches |
(27)3 that |
(39)2 group |
| (4)23 for |
(16)4 methods |
(28)2 a |
(40)2 groups |
| (5)22 with |
(17)4 option |
(29)2 as |
(41)2 may |
| (6)15 options |
(18)4 options, |
(30)2 at |
(42)2 ranks |
| (7)13 in |
(19)4 ranking |
(31)2 being |
(43)2 reduced |
| (8)9 effect |
(20)4 regimens |
(32)2 compared |
(44)2 resistance |
| (9)9 effects |
(21)4 strategies |
(33)2 decisions, |
(45)2 screening, |
| (10)8 is |
(22)3 adherence |
(34)2 development |
(46)2 through |
| (11)8 on |
(23)3 approach |
(35)2 did |
(47)2 were |
| (12)7 outcomes |
(24)3 or |
(36)2 dose |
add keyword
--- WordNet output for treatment ---